Secondary Hypogonadism Diagnostic Algorithm: Step by Step

Why Distinguishing Secondary From Primary Hypogonadism Matters

The treatment path diverges completely depending on where the defect sits. In secondary (hypogonadotropic) hypogonadism, the hypothalamus or pituitary fails to produce adequate gonadotropin-releasing hormone (GnRH), LH, or FSH. The testes themselves are functional. This distinction determines whether a man can preserve fertility with targeted therapy or requires exogenous testosterone, which suppresses spermatogenesis through negative feedback.

The Endocrine Society's 2018 clinical practice guideline defines male hypogonadism as "a clinical syndrome that results from failure of the testis to produce physiological concentrations of testosterone and/or a normal number of spermatozoa." In secondary hypogonadism specifically, the problem originates above the gonads. Dr. Shalender Bhasin, lead author of the Endocrine Society guideline, has stated: "Measurement of serum LH and FSH concentrations can help distinguish primary from secondary hypogonadism and should be performed before initiating testosterone therapy."

That single lab distinction changes everything. Miss it, and a man with a pituitary prolactinoma may receive testosterone injections while a tumor grows undetected. Catch it, and the same patient gets a dopamine agonist that normalizes both prolactin and testosterone within weeks.

Step 1: Clinical Suspicion and Symptom Assessment

Begin the algorithm when a male patient presents with symptoms consistent with testosterone deficiency. Common presentations include decreased libido, erectile dysfunction, fatigue, reduced muscle mass, depressed mood, and loss of morning erections. The AUA 2018 guideline recommends against screening asymptomatic men but advises testing when clinical features suggest deficiency.

Not every symptom warrants a workup. The Endocrine Society guideline lists specific conditions that should trigger testosterone measurement: type 2 diabetes, obesity with BMI >30, chronic opioid use, HIV-associated weight loss, end-stage renal disease on dialysis, moderate-to-severe COPD, and infertility [1]. A study published in the Journal of Clinical Endocrinology & Metabolism found that men with type 2 diabetes had a 33-50% prevalence of low testosterone, with the majority showing a secondary pattern [2].

Document symptoms systematically. Use a validated questionnaire such as the Androgen Deficiency in the Aging Male (ADAM) questionnaire or the quantitative ANDROTEST structured interview, though neither replaces biochemical confirmation.

Step 2: Confirm Low Testosterone With Two Morning Draws

Order a fasting total testosterone drawn before 10:00 AM. This timing matters because testosterone follows a circadian rhythm, peaking between 7:00 and 10:00 AM and dropping by 20-25% by afternoon [1]. A single low value is not diagnostic. The Endocrine Society requires confirmation with a second morning sample, ideally using the same assay and drawn on a separate day.

The diagnostic cutoff is total testosterone below 300 ng/dL (10.4 nmol/L). The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies involving 790 men aged 65 and older, used this threshold as an entry criterion [3]. If total T falls in the 200-400 ng/dL range and clinical suspicion remains high, measure free testosterone by equilibrium dialysis or calculate it using the Vermeulen equation. SHBG-altering conditions (obesity, liver disease, aging, thyroid disorders) can make total testosterone misleading.

Acute illness suppresses testosterone transiently. Do not test during hospitalization, acute infection, or within two weeks of surgery. Repeat testing after recovery.

Step 3: Measure LH and FSH to Localize the Defect

This is the branching point that separates primary from secondary hypogonadism. Order serum LH and FSH alongside the confirmatory testosterone draw.

Primary hypogonadism (hypergonadotropic): LH and FSH are elevated (>8-12 mIU/mL) because the pituitary is working overtime to compensate for testicular failure.

Secondary hypogonadism (hypogonadotropic): LH and FSH are low (<8 mIU/mL) or inappropriately normal in the setting of low testosterone. "Inappropriately normal" is the key phrase. An LH of 4 mIU/mL is technically within the reference range, but when testosterone is 180 ng/dL, it signals that the pituitary is not responding to the low-testosterone signal [1].

The AACE 2021 clinical practice guideline reinforces this framework and notes that "combined primary and secondary hypogonadism can occur, particularly in aging men and those with chronic systemic illness" [4]. In such mixed cases, LH may be mildly elevated but not proportionate to the degree of testosterone deficiency.

Step 4: Identify Reversible Causes Before Imaging

Once a secondary pattern is confirmed, the algorithm branches into functional (reversible) versus organic (structural) causes. Evaluate functional etiologies first because they are far more common and correctable without lifelong hormone therapy.

Obesity. The strongest single predictor. Data from the European Male Ageing Study (EMAS), a prospective cohort of 3,369 community-dwelling men aged 40-79, found that a BMI increase of 5 kg/m² was associated with a testosterone decline comparable to 10 years of aging [5]. Weight loss of 5-10% can raise testosterone by 50-100 ng/dL without any pharmacologic intervention. The mechanism involves excess aromatase activity in adipose tissue converting testosterone to estradiol, which suppresses GnRH pulsatility.

Medications. Opioids are the most common pharmacologic cause. A systematic review in the Journal of Clinical Endocrinology & Metabolism reported that 53-87% of men on chronic opioid therapy had biochemical hypogonadism, predominantly secondary [6]. Glucocorticoids, anabolic steroids (including exogenous testosterone from prior use), and high-dose progestins also suppress the HPG axis. Discontinuation or dose reduction should be attempted before starting testosterone replacement.

Hyperprolactinemia. Order a serum prolactin level. Mild elevations (25-100 ng/mL) can result from medications (antipsychotics, metoclopramide, SSRIs), stress, or a stalk effect from any sellar mass. Prolactin above 100 ng/mL raises strong suspicion for a prolactinoma.

Other functional causes. Uncontrolled type 2 diabetes, obstructive sleep apnea, excessive exercise, caloric restriction, hemochromatosis, and chronic illness all suppress gonadotropins. A ferritin level and transferrin saturation should be checked because hemochromatosis is a treatable cause of both pituitary iron deposition and secondary hypogonadism [1].

Step 5: Pituitary MRI, When and Why

Not every patient with secondary hypogonadism needs brain imaging. The Endocrine Society guideline recommends pituitary MRI with gadolinium in the following scenarios [1]:

• Total testosterone persistently below 150 ng/dL
• Prolactin above 100 ng/mL (some centers use >150 ng/mL)
• Any visual field defect on confrontation testing
• Severe or progressive headaches
• Signs of other pituitary hormone deficiencies (hypothyroidism, adrenal insufficiency, growth hormone deficiency)
• Age under 40 with no identifiable functional cause

A gadolinium-enhanced MRI of the sella turcica is the gold standard. CT is inferior for soft tissue resolution in the sella. If a macroadenoma (>10 mm) is identified, formal visual field testing (Humphrey perimetry) and a full anterior pituitary hormone panel (TSH, free T4, morning cortisol or ACTH stimulation test, IGF-1, prolactin) are mandatory. Referral to endocrinology or neurosurgery follows.

Microadenomas (<10 mm) are incidentally found in up to 10% of MRI scans. A nonfunctioning microprolactinoma may simply need surveillance. Functioning prolactinomas, regardless of size, respond to dopamine agonists (cabergoline 0.25-1.0 mg twice weekly is first-line), often normalizing testosterone without any direct testosterone intervention [7].

Step 6: Additional Hormonal and Genetic Testing

For patients under 30, congenital causes deserve consideration. Kallmann syndrome (anosmia plus hypogonadotropic hypogonadism) affects approximately 1 in 8,000 males and is clinically diagnosable by the combination of delayed puberty, absent or reduced sense of smell, and low gonadotropins [8]. Genetic testing for KAL1, FGFR1, and other associated genes is available but not always necessary when the clinical picture is clear.

Order a complete pituitary panel if any other axis appears affected. Measure:

• Morning cortisol (or ACTH stimulation test if borderline)
• TSH and free T4
• IGF-1 (growth hormone axis screen)
• Prolactin (if not already measured)
• Estradiol (particularly in obese men, to assess aromatization)
• Iron studies (ferritin, transferrin saturation)

The AACE 2021 guideline specifically recommends estradiol measurement in obese men because elevated estradiol from peripheral aromatization directly suppresses GnRH pulse frequency [4]. An estradiol level above 40-50 pg/mL in a man with secondary hypogonadism and BMI >30 supports aromatase excess as the functional mechanism.

Step 7: Treatment Selection Based on Fertility Goals

This is the most consequential clinical decision in the algorithm. Exogenous testosterone (injections, gels, patches, pellets) will suppress LH and FSH further, often reducing sperm count to zero within 3-6 months. For men who want to father children now or in the future, alternative approaches are recommended [1].

Fertility desired, pharmacologic options:

• Clomiphene citrate (25-50 mg daily or every other day, off-label): A selective estrogen receptor modulator that blocks hypothalamic estrogen receptors, increasing GnRH pulsatility and thereby LH/FSH secretion. A retrospective cohort study of 86 men showed mean total testosterone increased from 228 ng/dL to 612 ng/dL after a median of 3 months [9].
• Enclomiphene (12.5-25 mg daily): The trans-isomer of clomiphene with a shorter half-life, producing fewer estrogenic side effects. Phase 3 data showed mean testosterone normalization with preserved spermatogenesis [10].
• Human chorionic gonadotropin (hCG) (1,500-3 to 000 IU subcutaneously two to three times weekly): Directly stimulates testicular Leydig cells via the LH receptor while maintaining intratesticular testosterone needed for spermatogenesis.
• Pulsatile GnRH (via subcutaneous pump): Reserved for patients with hypothalamic GnRH deficiency, particularly congenital forms. Highly effective for inducing spermatogenesis but logistically complex.

Fertility not desired, testosterone replacement:

The AUA 2018 guideline states that testosterone therapy is appropriate for men with confirmed hypogonadism and bothersome symptoms who do not desire fertility [11]. Standard regimens include testosterone cypionate 100-200 mg intramuscularly every 1-2 weeks, testosterone gel 1% (50 mg daily), or testosterone undecanoate 750 mg intramuscularly every 10 weeks after loading.

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine, demonstrated that testosterone replacement in men aged 45-80 with hypogonadism and cardiovascular risk factors did not increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months [12]. This trial addressed a long-standing safety concern and changed practice for many clinicians.

Step 8: Monitoring and Follow-Up Schedule

After initiating treatment, structured follow-up prevents both undertreatment and complications. The Endocrine Society recommends the following schedule [1]:

At 3 months: Measure total testosterone (trough level for injections, midmorning for gels). Check hematocrit. Assess symptom response. For patients on clomiphene or hCG, add LH, FSH, and estradiol.

At 6 and 12 months: Repeat testosterone, hematocrit, PSA (for men over 40), and lipid panel. Perform a semen analysis if the patient is on fertility-preserving therapy and attempting conception.

Annually thereafter: Testosterone, hematocrit, PSA, metabolic panel. Bone density (DXA scan) at baseline and 1-2 years for men with osteoporosis or low bone mass.

Hematocrit above 54% requires dose reduction or temporary discontinuation of testosterone. This is the most common adverse effect of testosterone therapy, occurring in 3-18% of treated men depending on the route and dose [1]. Dr. Bradley Anawalt, an Endocrine Society guideline panel member, has noted: "Polycythemia is dose-related, route-related, and the main reason we monitor hematocrit regularly in men receiving testosterone."

For patients with secondary hypogonadism due to reversible causes, schedule a reassessment at 6-12 months after the cause is addressed (weight loss achieved, opioid discontinued, prolactinoma treated). If testosterone normalizes, therapy can be tapered and withdrawn with ongoing surveillance to ensure levels remain in the physiologic range.